JACKSONVILLE, Fla., June 11, 2026
Johnson & Johnson has announced the expanded U.S. availability of its TECNIS PureSee Intraocular Lens (IOL), an advanced extended depth of focus (EDOF) lens designed to improve visual outcomes for patients undergoing cataract surgery. The expanded rollout comes during Cataract Awareness Month and aims to provide cataract surgeons and patients with greater access to a next-generation vision correction option that addresses both cataract-related vision impairment and the effects of age-related presbyopia. The company also introduced a new patient lifestyle quiz intended to support informed discussions between patients and eye care professionals when selecting intraocular lens options ahead of surgery. According to Johnson & Johnson, more than 500,000 eyes worldwide have already benefited from the TECNIS PureSee platform, highlighting growing adoption of advanced ophthalmic technologies in cataract care.
Advanced Lens Technology Expands Vision Correction Options
The TECNIS PureSee IOL has been developed to deliver an extended range of vision while maintaining visual quality comparable to traditional monofocal lenses. The lens is designed to provide excellent distance and intermediate vision, along with functional near vision, helping patients perform everyday activities with greater independence following cataract surgery. Johnson & Johnson reported that 97% of patients would recommend the TECNIS PureSee IOL to family members or friends, while a similar percentage reported no highly bothersome visual disturbances.
The technology is particularly notable because it is the first and only FDA-approved EDOF intraocular lens in the United States without a warning related to contrast sensitivity loss, a critical factor affecting visual performance in low-light environments. By maintaining contrast sensitivity comparable to aspheric monofocal lenses while extending the range of vision, the lens seeks to offer a balance between visual quality and spectacle independence. Cataracts remain one of the leading causes of vision impairment globally, affecting millions of adults and significantly impacting quality of life.
Addressing Cataracts and Presbyopia in a Single Procedure
Advertisement
The expanded availability of TECNIS PureSee IOL arrives at a time when healthcare providers are increasingly focused on personalized ophthalmic care. Cataract surgery remains one of the most frequently performed and safest surgical procedures worldwide, with success rates approaching 98%. During the procedure, surgeons remove the clouded natural lens and replace it with an artificial intraocular lens. The TECNIS PureSee IOL offers an additional benefit by addressing presbyopia, the age-related loss of near vision that affects nearly everyone over the age of 50. Through its extended depth of focus design, the lens enables patients to achieve a broader range of vision without significantly compromising image quality.
Johnson & Johnson stated that the product builds upon the trusted TECNIS platform, giving surgeons greater flexibility in tailoring vision correction solutions to individual patient lifestyles and visual expectations. As demand grows for premium cataract surgery options, technologies that combine cataract treatment with refractive correction are becoming increasingly important within modern ophthalmology.
Supporting Patient Education and Ophthalmic Innovation
To complement the expanded rollout, Johnson & Johnson launched a new patient lifestyle assessment tool designed to help individuals better understand their visual goals before surgery. The initiative reflects a broader industry trend toward patient-centered healthcare and shared decision-making. By encouraging discussions about daily activities, work requirements, and vision expectations, the company hopes to improve patient awareness of available treatment options and optimize postoperative satisfaction.
The announcement also reinforces Johnson & Johnson’s ongoing investment in ophthalmic innovation, vision care technologies, and advanced medical devices. As the global burden of cataracts and age-related vision disorders continues to rise, innovations such as the TECNIS PureSee IOL are expected to play an increasingly important role in enhancing visual outcomes and improving quality of life for aging populations worldwide.
Source: Johnson & Johnson press release
